CanSino Biologics Inc. (688185.SH) announced that the company's ACYW135 group meningococcal polysaccharide conjugate vaccine (...)
According to the Zhitong Finance APP, CanSino Biologics Inc. (688185.SH) announced that its ACYW135 meningococcal polysaccharide-conjugate vaccine (CRM197 carrier), referred to as "MCV4", has recently received a registration certificate from the Indonesian Food and Drug Administration.
MCV4 is suitable for infants and young children aged 3 months to 3 years (47 months). Vaccination can stimulate the body to produce immunity against ACYW135 meningococcal bacteria, used for the prevention of epidemic meningitis caused by ACYW135 meningococcus, showing good safety and immunogenicity in clinical trials conducted domestically.